Orthopoxvirus mature virion surface antigens (MV surface antigens)

Orthopoxvirus mature virion (MV) surface antigens are a collection of highly conserved proteins located on the external membrane of the mature virion, the most abundant infectious form of orthopoxviruses such as Variola (smallpox), Monkeypox, and Vaccinia viruses. Key proteins in this group include L1, A27, H3, and D8, which play critical roles in viral attachment to host cell receptors, such as glycosaminoglycans, and facilitate the fusion of the viral envelope with the plasma or endosomal membranes (PubMed: 15140980, UniProt: P09152). These antigens are the primary targets for neutralizing antibodies generated by vaccination or administered via immune globulin therapy, making them central to the prevention and control of orthopoxvirus infections. Because the MV form is responsible for person-to-person transmission and initial infection, targeting these surface antigens is a fundamental strategy in the development of next-generation subunit vaccines and monoclonal antibody cocktails (PubMed: 18032494). Therapeutic intervention against these antigens aims to neutralize the virus before it can enter host cells, thereby limiting viral replication and disease severity.

Other names

Orthopoxvirus MV surface proteinsMature virion membrane proteinsL1R proteinA27L proteinH3L proteinD8L proteinA17L protein

Vaccines and immune globulins target these antigens to elicit or provide neutralizing antibodies that block viral attachment, entry, and fusion with host cells. While drugs like Tecovirimat target the p37 protein to prevent the formation of extracellular enveloped virions (EEV), the mature virion (MV) surface antigens are the primary targets for preventing the initial infection and spread of the MV form of the virus (PubMed: 16148232, NIH: NBK574529).